PITTSBURGH, May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024. Chief Executive Officer Scott A. Smith and Company executives will represent the company in a fireside chat scheduled at 8 a.m. ET. SOURCE Viatris Inc. About Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to br ...

DNY59 In our last coverage of Viatris Inc. (NASDAQ?VTRS) we pointed out that the company was the epitome of a value trap. It looked cheap and appealed to the "low "P/E" crowd. But the melting ice cube prevented any returns for all but those that bought the extreme dips and sold the minor rips. The chart below shows the performance of VTRS and its predecessor, Mylan Labs. Mylan Labs was combined with the generic unit of Pfizer Inc. (PFE) and started trading as VTRS in November 2020. VAI Viatris Inc (VTRS) Pr ...

Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH, May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building ...

业绩总结 - Viatris Inc. 公司在北美地区的品牌产品包括Yupelri和Tyrvaya，以及现有的复杂通用药品如Wixela，预计全年总收入将实现2%的运营增长[5] - 欧洲业务预计将增长3%，主要受益于在意大利和法国等关键市场的广泛产品组合，以及新产品推出，如新兴市场的通用Aubagio[6] - 中国市场约95%的业务已经通过VBP，公司专注于继续执行并引入新产品，如Clopidogrel和Senarimad，以利用现有基础设施[13] 市场扩张和并购 - 公司寻求全球机会，利用全球基础设施，与生物制药公司合作，推动在美国以及全球范围内的增长[34] - 公司强调寻找具有全球权利的资产，以最大化价值，并强调资产的商业化比商业考虑更为重要[33] 负面信息 - Clopidogrel是一项用于预防急性心肌梗死的独特且新颖的临床试验[41] - 通过增加研究站点数量和重新与调查员亲密合作，Viatris正在加速Clopidogrel的招募速度[42][43] - Clopidogrel填补了心肌梗死治疗中的空白，通过自行注射药物来阻止心肌梗死的进展[45] - 临床试验的终点是在七天内死亡以及严重心肌梗死的发生率，旨在展示治疗组与安慰剂组之间的风险降低20%[50][51] - 患者是否正确注射药物对层次分析的影响，但最终结果将基于事件，而不考虑是否正确注射[53][54] - 监控数据表明患者在出现症状后30分钟内注射药物，并及时就医，且未出现严重出血迹象[55][57] - Viatris认为Clopidogrel是一种具有革命性意义的治疗方法，得到了临床界的支持[60][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other juris ...

Viatris Inc. (VTRS) delivered adjusted earnings of 67 cents per share in the first quarter of 2024, missing the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 77 cents in the year-ago quarter.Total revenues came in at $3.66 billion, down 1.7% year over year. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.7 million.Viatris’ stock is trading down in response to the first-quarter results mainly due to a miss on both earn ...

Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conference Call Participants Nathan Rich - Goldman Sachs Bhavin Patel - Bank of America Glen Santangelo - Jefferies Ash Verma - UBS Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning and welcome to Viatris Q1 2024 Earnings Conference Call. ...

文章核心观点 - Viatris公司在2024年第一季度的财务表现略低于市场预期，尽管股价在过去一个月有所上涨 [1][2][10] 财务表现 - 公司报告的季度收入为36.6亿美元，同比下降1.8% [1] - 每股收益（EPS）为0.67美元，相比去年同期的0.78美元有所下降 [1] - 收入低于Zacks Consensus Estimate的37.4亿美元，差距为-2.12% [2] - EPS低于市场预期的0.68美元，差距为-1.47% [2] 关键指标表现 - 发达市场净销售额为21.7亿美元，同比下降0.2%，低于分析师平均预期的22.6亿美元 [5] - 大中华区净销售额为5.439亿美元，同比下降3.7%，略高于分析师平均预期的5.1824亿美元 [6] - 其他收入为990万美元，同比下降1%，略低于分析师平均预期的1000万美元 [7] - 新兴市场净销售额为6.264亿美元，同比下降2.4%，低于分析师平均预期的6.4313亿美元 [8] - 总净销售额为36.5亿美元，同比下降1.8%，略低于分析师平均预期的37.3亿美元 [9] - JANZ地区净销售额为3.178亿美元，同比下降7.1%，略高于分析师平均预期的3.1247亿美元 [9] 股价表现 - Viatris股价在过去一个月上涨了0.9%，而Zacks S&P 500综合指数下跌了0.3% [10] - 公司目前持有Zacks Rank 3（持有），表明其短期内可能与更广泛的市场表现相当 [10]

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.67 per share when it actually produced earnings of $0.61, delivering a surprise of -8.96%.Over the last four quarters, the compan ...

Lara Ramsburg Chief Corporate Affairs Officer Brian Roman Chief Legal Officer Q1 2024 Select Key Product Net Sales, on a Consolidated Basis 22 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Full-Year 2024 Guidance Items as of May 9, 2024(1) | --- | --- | |--------------------- ...